Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M CHANDA

Showing results (41-50 of 45) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 45 results.
Pharmacology Research & Perspectives|May 9, 2018
Pharmacokinetics, safety, and tolerability of the 2- and 3-direct-acting antiviral combination of AL-335, odalasvir, and simeprevir in healthy subjectsThomas N Kakuda, Matthew W McClure, Christopher Westland, et al.
Journal of Medicinal Chemistry|February 11, 2015
Discovery of 4'-chloromethyl-2'-deoxy-3',5'-di-O-isobutyryl-2'-fluorocytidine (ALS-8176), a first-in-class RSV polymerase inhibitor for treatment of human respiratory syncytial virus infectionGuangyi Wang, Jerome Deval, Jin Hong, et al.
Transboundary and Emerging Diseases|December 23, 2016
Dual Infection with Bluetongue Virus Serotypes and First-Time Isolation of Serotype 5 in IndiaD Hemadri, S Maan, M M Chanda, et al.
PLOS Global Public Health|March 24, 2023
Co-production of knowledge as part of a OneHealth approach to better control zoonotic diseasesFestus A Asaaga, Juliette C Young, Prashanth N Srinivas, et al.
The Lancet. Infectious Diseases|May 10, 2014
Early versus delayed initiation of highly active antiretroviral therapy for HIV-positive adults with newly diagnosed pulmonary tuberculosis (TB-HAART): a prospective, international, randomised, placebo-controlled trialSayoki G Mfinanga, Bruce J Kirenga, Duncan M Chanda, et al.
Pageof 5

Showing results (41-50 of 45) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 45 results.
Pharmacology Research & Perspectives|May 9, 2018
Pharmacokinetics, safety, and tolerability of the 2- and 3-direct-acting antiviral combination of AL-335, odalasvir, and simeprevir in healthy subjectsThomas N Kakuda, Matthew W McClure, Christopher Westland, et al.
Journal of Medicinal Chemistry|February 11, 2015
Discovery of 4'-chloromethyl-2'-deoxy-3',5'-di-O-isobutyryl-2'-fluorocytidine (ALS-8176), a first-in-class RSV polymerase inhibitor for treatment of human respiratory syncytial virus infectionGuangyi Wang, Jerome Deval, Jin Hong, et al.
Transboundary and Emerging Diseases|December 23, 2016
Dual Infection with Bluetongue Virus Serotypes and First-Time Isolation of Serotype 5 in IndiaD Hemadri, S Maan, M M Chanda, et al.
PLOS Global Public Health|March 24, 2023
Co-production of knowledge as part of a OneHealth approach to better control zoonotic diseasesFestus A Asaaga, Juliette C Young, Prashanth N Srinivas, et al.
The Lancet. Infectious Diseases|May 10, 2014
Early versus delayed initiation of highly active antiretroviral therapy for HIV-positive adults with newly diagnosed pulmonary tuberculosis (TB-HAART): a prospective, international, randomised, placebo-controlled trialSayoki G Mfinanga, Bruce J Kirenga, Duncan M Chanda, et al.
Pageof 5